TD Cowen raises 10X Genomics stock price target on Atera growth
TD Cowen raised its price target for 10X Genomics (NASDAQ:TXG) to $70 from $47, citing increased revenue estimates and growth in Atera sales. The stock has gained 548% over the past year. Analysts have mixed views on the company's future, with some highlighting strong demand for Atera and others expressing caution. 10X Genomics reported Q2 2026 revenue of $151.04 million, beating estimates.
How this was made
The 30-second read
Why it matters
The upgrade may attract new buying interest, especially from investors seeking exposure to AI‑enabled genomics tools.
Market read
Analyst price‑target increase could prompt short‑term upside for TXG and influence sentiment in the genomics sector.
What to watch
Potential AI integration challenges and slower pharma adoption may delay revenue upside.
Background
TD Cowen upgraded 10X Genomics based on its Atera spatial biology platform, raising revenue forecasts and price target.
Ticker impact
TD Cowen raised its price target on 10X Genomics to $70 from $47, citing Atera platform growth and higher revenue estimates.
likely upward pressure as investors price in the higher target and revenue outlook
The new $70 target is substantially above the current price and reflects a 9% revenue estimate lift, which typically prompts short‑term buying.
Market effects
Positive outlook for spatial biology and single‑cell genomics may lift peers in the life‑science tools sector.
US biotech market may see modest gains as the upgrade adds to sector momentum.
Limited to investors focused on genomics and AI‑driven biotech platforms.
Counterpoint
The Atera platform could face cannibalization from Visium and Xenium, tempering growth expectations.
Key entities
- company10X Genomics
Provider of single‑cell and spatial genomics platforms, ticker TXG.
- analystTD Cowen
Equity research firm that issued the price‑target raise.
